Incorrect password
evipedia.ai Suggest Edit

Andrographis for Health & Longevity

Evidence Review created on 05/01/2026 using AI4L / Opus 4.7

Also known as: Andrographis paniculata, Kalmegh, King of Bitters, Chuan Xin Lian, Green Chiretta, Indian Echinacea, Creat

Motivation

Andrographis is a bitter herb (Andrographis paniculata) native to India and Sri Lanka, long employed in Ayurveda and Traditional Chinese Medicine for fevers, infections, and digestive complaints. Its extreme bitterness earned it the names “King of Bitters” and Kalmegh, and its primary bioactive compound, andrographolide, has drawn modern scientific interest for anti-inflammatory, antiviral, and immunomodulatory effects.

Although best known in Western markets as a remedy for the common cold and flu, andrographis has also been investigated for inflammatory bowel and joint conditions. Standardized extracts have been a fixture of European phytotherapy for decades, while pharmaceutical-grade preparations have advanced into late-phase trials for inflammatory bowel disease, and several modern brand-standardized products now anchor much of the clinical literature.

This review examines the clinical and mechanistic evidence for andrographis across immune, anti-inflammatory, and adjacent health domains, and lays out the practical details needed to judge whether it has a place in a broader longevity-oriented strategy.

Benefits - Risks - Protocol - Conclusion

A curated selection of accessible, high-level resources on andrographis, its bioactive compounds, and its clinical use for immune and inflammatory conditions.

  • The Top 20 Natural Remedies for Cold and Flu - Chris Kresser

    Practitioner-oriented article that lists andrographis among 20 evidence-informed botanicals for cold and flu, summarizes its anti-inflammatory and antiviral activity, and gives a clinical dose range of 400 mg three times daily up to 1,000–2,000 mg three times daily of andrographolide-standardized extract for short-term use.

  • Optimal Arthritis Control - Julius Goepp

    Magazine feature explaining how andrographolides target the TNF-alpha (tumor necrosis factor alpha, a master inflammatory signal) and NF-κB (nuclear factor kappa B, a master regulator of inflammatory gene expression) inflammatory cascade in rheumatoid arthritis, with a multi-target rationale for combining andrographis with curcumin and other natural anti-inflammatories.

  • Andrographis - Memorial Sloan Kettering Cancer Center

    Integrative-medicine herb monograph from a major cancer center summarizing andrographis’s traditional uses, clinical evidence for upper respiratory infections, ulcerative colitis, and multiple sclerosis fatigue, mechanism of action, drug interactions, contraindications (notably pregnancy and immunosuppression), and warnings about hepatic and allergic adverse events.

  • Andrographis: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - Chelsey McIntyre

    Consumer-facing overview that catalogues andrographis’s traditional and proposed uses, evidence ratings, common side effects, drug interactions, and typical dosing, useful as a lay-audience entry point and reference on commonly available product forms.

Only four high-quality, directly relevant items are listed. Examine.com and ConsumerLab content are covered in their own dedicated sections below and are therefore excluded here, and systematic reviews and meta-analyses are reserved for the dedicated Systematic Reviews section. No directly relevant, substantive content discussing andrographis was found from Rhonda Patrick on foundmyfitness.com, Peter Attia on peterattiamd.com, or Andrew Huberman on hubermanlab.com. Their platforms cover general immune support topics, but none has a dedicated andrographis discussion.

Grokipedia

Andrographis paniculata

Comprehensive entry describing andrographis as an erect annual herbaceous plant in the Acanthaceae family native to India, Sri Lanka, and parts of Southeast Asia, with detailed coverage of taxonomy, morphology, phytochemistry (with andrographolide as the principal labdane diterpenoid), traditional Ayurvedic and Traditional Chinese Medicine use, modern clinical evidence for upper respiratory tract infections, and known limitations including extract heterogeneity and rare hepatic adverse events.

Examine

Andrographis paniculata

Examine’s dedicated andrographis page summarizes the herb’s primary use as a cold remedy when taken at the first sign of symptoms for three to five days, lists typical oral doses of 2,000–6,000 mg/day of basic root extract (or standardized andrographolide-containing extracts), notes that much of the human evidence is for combination products with Eleutherococcus senticosus (Siberian ginseng), and reviews preclinical anti-cancer and anti-inflammatory data.

ConsumerLab

Andrographis for Colds, Arthritis and More

ConsumerLab’s expert review summarizing the clinical evidence for andrographis across respiratory infections (including colds and COVID-19), osteoarthritis, rheumatoid arthritis, ulcerative colitis, multiple sclerosis, and cancer; addressing safety, including rare elevated liver enzymes and anaphylactic reactions; and reporting that approximately one in five andrographis supplements sold on Amazon was of poor quality on recent independent analysis.

Systematic Reviews

A selection of systematic reviews and meta-analyses evaluating andrographis’s clinical efficacy and safety across its most studied domains.

Mechanism of Action

Andrographis’s biological effects are driven primarily by andrographolide and related diterpene lactones (neoandrographolide, deoxyandrographolide, andrographiside) acting on multiple inflammatory and immune pathways:

  • NF-κB pathway inhibition: Andrographolide covalently modifies a cysteine residue on the p50 subunit of NF-κB, blocking its binding to DNA and downstream transcription of inflammatory genes. This is considered the central mechanism behind andrographis’s broad anti-inflammatory profile
  • TNF-alpha and cytokine suppression: Through NF-κB blockade and direct effects on macrophages, andrographis reduces production of TNF-alpha, IL-1-beta (interleukin-1-beta, an early-warning inflammatory cytokine), IL-6 (a pro-inflammatory cytokine involved in immune responses), and several chemokines, while sparing or modestly enhancing anti-inflammatory IL-10
  • T-cell modulation: Preclinical work, including studies of the HMPL-004 extract in murine colitis, shows that andrographis inhibits T-cell proliferation and biases adaptive immunity away from Th1 (T-helper 1, a subset of CD4+ T cells driving cellular immunity and certain autoimmune responses) and Th17 (T-helper 17, a CD4+ T-cell subset implicated in autoimmunity and chronic inflammation) responses, providing a rationale for its use in inflammatory bowel disease and autoimmune fatigue
  • Antiviral activity: Andrographolide directly inhibits viral entry, replication, and main protease activity of several respiratory and arboviruses in cell culture, including influenza A, SARS-CoV-2, dengue, and human rhinovirus, primarily by binding viral proteins and disrupting host signaling that supports viral assembly
  • Antiplatelet and vascular effects: Andrographolide inhibits platelet aggregation through PAF (platelet-activating factor, a phospholipid mediator of platelet activation and inflammation) receptor antagonism and reduces oxidized LDL-induced endothelial dysfunction in preclinical models, contributing to potential cardiovascular and bleeding-risk considerations
  • Hepatic and antioxidant effects: Andrographis upregulates Nrf2 (nuclear factor erythroid 2-related factor 2, a master regulator of antioxidant gene expression) and downstream phase II detoxification enzymes, with mixed effects on hepatic CYP enzymes; it has shown both hepatoprotective effects in toxin-induced liver injury models and rare hepatotoxic signals in clinical use
  • Glucose regulation: Animal studies and small human trials suggest andrographis may improve insulin sensitivity, enhance GLUT4 (glucose transporter type 4, the insulin-responsive glucose transporter in muscle and fat) expression, and modestly lower fasting glucose, although the human evidence remains limited
  • Pharmacokinetic properties: Andrographolide is rapidly absorbed orally with a peak plasma level (Tmax) of approximately 1.5–2 hours and an elimination half-life of approximately 2 hours. Bioavailability is non-linear and limited by efflux transporters and rapid sulfation/glucuronidation. Andrographolide is not selective for a single molecular target — it acts as a multi-target compound with documented effects on NF-κB, TNF-alpha, multiple cytokines, viral proteins, platelet receptors, Nrf2, and glucose-regulatory pathways. Tissue distribution after oral dosing is broad: animal radiolabel and PK studies show it reaches the liver, kidneys, spleen, lungs, gastrointestinal tract, and (at lower levels) brain, with the highest concentrations in liver and gut. Metabolism involves hepatic phase II conjugation more than CYP-mediated phase I oxidation; however, andrographis extracts can inhibit CYP3A4 (cytochrome P450 3A4, a major drug-metabolizing liver enzyme) and CYP1A2 (cytochrome P450 1A2, a liver enzyme that metabolizes caffeine and several drugs) in vitro and may interact with co-administered drugs

Historical Context & Evolution

Andrographis is one of the most thoroughly traditionally documented herbs to enter modern phytotherapy:

  • Pre-1800s: Andrographis was a foundational herb in Ayurveda, Siddha, and Unani medicine, used as Kalmegh (Sanskrit for “dark cloud”) for fevers, malaria, jaundice, snakebite, and digestive complaints; in Traditional Chinese Medicine it was known as Chuan Xin Lian and classified as a “cold” herb for clearing heat and toxins, primarily for sore throat, dysentery, and respiratory infections
  • 1700s–1800s: During the Indian colonial period, British East India Company physicians documented andrographis as a substitute for quinine in malaria, contributing to its early Western reputation as a febrifuge
  • 1919 Indian flu epidemic: Andrographis became widely used in India during the 1918–1919 influenza pandemic and was credited locally with stemming the epidemic, cementing its place in popular Indian use for respiratory infections
  • 1950s–1970s: Indian and Chinese pharmacology programs systematically isolated andrographolide and characterized its anti-inflammatory and antimicrobial activity; by the 1970s standardized andrographolide content became a benchmark for herb quality
  • 1980s–1990s: Scandinavian companies (notably Swedish Herbal Institute) developed Kan Jang, a fixed combination of andrographis and Eleutherococcus senticosus (Siberian ginseng), and ran the first wave of European randomized controlled trials in upper respiratory tract infection
  • 2000s: A wave of meta-analyses, including Coon and Ernst’s 2004 review and the Cochrane-style assessments that followed, established andrographis (alone or in Kan Jang) as superior to placebo for symptomatic relief of acute respiratory tract infection while highlighting study heterogeneity
  • 2010s: A Chinese pharmaceutical company developed HMPL-004, a defined andrographis extract, as an investigational drug for inflammatory bowel disease, with two phase II trials in active ulcerative colitis (Tang et al., 2011; Sandborn et al., 2013) showing efficacy comparable to mesalazine in some endpoints; subsequent phase III development was eventually deprioritized
  • 2020s: Andrographis re-entered mainstream attention during the COVID-19 pandemic, with Thailand’s public health system formally endorsing andrographis for early-symptom outpatient treatment in 2021; subsequent randomized trials and the 2025 Prabhakornritta meta-analysis tempered initial enthusiasm, finding no significant improvement in fever or cough resolution versus standard care
  • Recent years: Branded standardized extracts (notably ParActin) have driven new randomized trials in osteoarthritis and rheumatoid arthritis, broadening the evidence base beyond respiratory indications

Expected Benefits

High 🟩 🟩 🟩

Acute Respiratory Tract Infection Symptom Relief

Andrographis is one of the most consistently studied botanical interventions for acute respiratory tract infections, with multiple large meta-analyses supporting a clinically meaningful benefit. The Hu et al. 2017 meta-analysis of 33 RCTs (7,175 patients) found significant reductions in cough (SMD -0.39) and sore throat (SMD -1.13) versus placebo, and the Wagner et al. 2015 cough-focused meta-analysis reported a large pooled effect (SMD -1.00). Most positive trials used standardized andrographolide-containing extracts (typically the Kan Jang product, manufactured and substantially studied by the Swedish Herbal Institute, or pure andrographolide-standardized extracts) at doses delivering 60–300 mg of andrographolide daily for 3–7 days, started within 72 hours of symptom onset; this manufacturer involvement in much of the underlying literature is a notable structural factor. Methodological quality varies, and effect sizes for individual symptoms are larger than those typically seen with echinacea or Pelargonium sidoides.

Magnitude: Approximately 0.4–1.1 standardized mean difference reduction in cough and sore throat severity versus placebo across pooled trials; symptom-relief effects typically appear within 24–48 hours of starting treatment.

Medium 🟩 🟩

Active Ulcerative Colitis Induction of Response

The pharmaceutical-grade andrographis extract HMPL-004 (developed and sponsored by Hutchison MediPharma, the manufacturer with a direct commercial interest in the result) has been tested in two phase II RCTs for active ulcerative colitis. Tang et al. 2011 (n = 120) found 1,200 mg/day comparable to slow-release mesalazine on clinical response (76% vs. 82%) and remission, and Sandborn et al. 2013 (n = 224) reported significantly higher clinical response at 1,800 mg/day versus placebo (60% vs. 40%) at 8 weeks, with similar adverse event profiles. The mechanism is thought to involve T-cell suppression and Th1/Th17 inhibition. Effects are most studied for induction rather than maintenance.

Magnitude: Approximately 20-percentage-point absolute increase in 8-week clinical response over placebo at 1,800 mg/day of HMPL-004 in active ulcerative colitis.

Osteoarthritis and Joint Pain Reduction

A double-blind, placebo-controlled RCT of standardized Andrographis paniculata extract (ParActin) in 103 patients with knee osteoarthritis (Hancke et al. 2019, manufacturer-funded by HPIngredients/Vedic Lifesciences) reported significantly greater reductions in pain (visual analog scale and WOMAC, the Western Ontario and McMaster Universities Osteoarthritis Index, a validated questionnaire of osteoarthritis pain and function, pain subscale) at 300 mg/day for 12 weeks. A separate 2021 trial extending exposure to 336 days similarly reported sustained pain and disease-progression benefits. The proposed mechanism is NF-κB and TNF-alpha inhibition reducing synovial inflammation.

Magnitude: Approximately 30–50% greater reduction in pain scores versus placebo over 12 weeks at 300 mg/day standardized extract.

Low 🟩

Multiple Sclerosis Fatigue Reduction

A 12-month double-blind placebo-controlled pilot study (Bertoglio et al. 2016) in relapsing-remitting multiple sclerosis (n = 25) tested 170 mg twice daily of a purified Andrographis paniculata extract and reported significantly greater reductions in fatigue scores versus placebo, with no effect on relapse rate or disability. The pilot scale and single-trial nature limit confidence, and downstream replication in larger cohorts has been slow.

Magnitude: Approximately 20–30% greater reduction in fatigue scores versus placebo in a single small pilot RCT.

Rheumatoid Arthritis Symptom Reduction

Smaller RCTs of andrographis (alone or in combination with curcumin/turmeric) have reported modest reductions in tender and swollen joint counts and inflammatory markers in rheumatoid arthritis. Effects are mechanistically aligned with andrographis’s TNF-alpha and NF-κB inhibition. The evidence base is small and primarily supports adjunctive rather than monotherapy use.

Magnitude: Not quantified in available studies.

Insulin Sensitivity Improvement ⚠️ Conflicted

A small clinical trial in metformin-treated type 2 diabetes (Widjajakusuma et al. 2019) and an Indonesian study evaluating GLP-1 (glucagon-like peptide-1, an incretin hormone that increases insulin secretion and slows gastric emptying), fasting insulin, and HOMA-IR (homeostasis model assessment of insulin resistance, a calculated index of insulin resistance from fasting glucose and insulin) reported modest improvements in insulin sensitivity. Animal studies are more consistent, showing increased GLUT4 expression and lower fasting glucose. Human evidence is limited and conflicted, with some trials showing no significant glycemic benefit.

Magnitude: Approximately 5–15% reductions in fasting glucose or HOMA-IR in small trials and animal models; not consistently replicated.

Speculative 🟨

Anticancer Adjunctive Effects

Andrographolide has shown anti-proliferative, pro-apoptotic, and anti-angiogenic effects against multiple human cancer cell lines (gastric, colorectal, hepatocellular, breast, prostate) and in animal xenograft models. A small phase III trial in advanced esophageal squamous cell carcinoma (NCT04196075) and isolated case-series data in palliative cancer care have been reported. Whether these in vitro and animal effects translate into human clinical benefit remains unestablished.

Hepatoprotective Effects

Animal studies show andrographis reduces hepatic injury from carbon tetrachloride, paracetamol, and alcohol, and a 2023 narrative review summarizes a broad preclinical literature on liver disease applications. Human trials are sparse, and the picture is complicated by rare hepatotoxic case reports in clinical use.

COVID-19 Symptom Reduction

Despite Thailand’s adoption of andrographis for early-symptom COVID-19, the 2025 Prabhakornritta meta-analysis of 6 RCTs found no significant benefit on fever or cough resolution and no significant reduction in CRP or IL-6 versus standard care, while the Dafur 2024 antimicrobial review confirmed antiviral activity of andrographolide against SARS-CoV-2 only in vitro. The clinical benefit remains unsupported by current trial-level evidence.

Cognitive and Neuroprotective Effects

A small phase I exploratory study (NCT03780621) tested an andrographis-and-Withania somnifera combination on EEG (electroencephalography, a measure of brain electrical activity) markers in mild cognitive impairment. Animal models suggest andrographolide may reduce neuroinflammation in models of Alzheimer’s disease and stroke. Human evidence is preliminary.

Benefit-Modifying Factors

  • Extract type and standardization: Benefit depends heavily on the specific preparation. Most positive respiratory trials used standardized extracts delivering 60–300 mg/day of andrographolide (e.g., Kan Jang, Paractin, HMPL-004), while non-standardized whole-herb products of variable composition show smaller and less consistent effects
  • Timing of initiation for respiratory infections: Benefits are largest when andrographis is started within the first 24–72 hours of symptom onset; later initiation produces smaller or null effects on cough and sore throat duration
  • Baseline biomarker levels: Individuals with higher baseline systemic inflammation (elevated hs-CRP, ESR, erythrocyte sedimentation rate, a non-specific inflammatory marker) and Th1/Th17-driven autoimmune activity (psoriasis, rheumatoid arthritis, ulcerative colitis) appear more likely to show measurable inflammatory and symptom improvement than otherwise healthy adults
  • Genetic polymorphisms: Polymorphisms in CYP3A4 and CYP1A2 may influence interactions with co-medications and indirectly modify the net benefit-risk balance, but no direct pharmacogenomic guidance for andrographis dosing exists
  • Sex-based differences: Most trials have included both sexes, and meta-analyses have not identified major sex-based differences in respiratory or anti-inflammatory efficacy; small osteoarthritis trials have been mixed-sex without sex-stratified efficacy reporting
  • Pre-existing health conditions: Active autoimmune disease or systemic inflammation may enhance the apparent anti-inflammatory benefit but also raises the risk of immune-mediated adverse reactions; gastrointestinal disorders may worsen with the herb’s bitter, secretagogue properties
  • Age-related considerations: Most trials have been in adults 18–65; pediatric efficacy data are limited but suggest comparable cough/sore-throat benefits, and trials in older adults are sparse despite plausible benefit in immunosenescence (the gradual decline of immune function with age)

Potential Risks & Side Effects

High 🟥 🟥 🟥

No high-evidence risks of serious harm have been identified. The Worakunphanich 2021 meta-analysis pooled a serious adverse event incidence of 0.02 per 1,000 patients (95% CI 0.0–0.5) across 10 RCTs and 3 intensive monitoring studies, indicating that serious harm at standard short-term doses is very rare.

Medium 🟥 🟥

Common Mild Adverse Events

Approximately 10% of users experience non-serious adverse events on standard short-term andrographis dosing. The Worakunphanich 2021 meta-analysis found a pooled non-serious adverse event incidence of 102.6 per 1,000 patients (95% CI 10.7–256.1), most commonly gastrointestinal (nausea, abdominal discomfort, diarrhea, loss of appetite) and cutaneous/subcutaneous (rash, pruritus). Most events are mild, dose-related, and resolve on discontinuation.

Magnitude: Approximately 10% incidence of mild gastrointestinal or skin-related adverse events at standard short-term doses across pooled RCTs.

Allergic Reactions

Andrographis can trigger allergic reactions ranging from mild urticaria (hives, raised itchy welts on the skin) and rash to, rarely, anaphylaxis (a severe, life-threatening allergic reaction). The herb is a member of the Acanthaceae family but cross-reactivity with common ragweed-family allergens is uncertain. ConsumerLab and Memorial Sloan Kettering both list rare anaphylactic reactions; pharmacovigilance data from European phytotherapy markets have flagged angioedema (sudden swelling of skin and mucosal tissues, often involving lips, tongue, or airway) and severe rash as uncommon but reported events.

Magnitude: Not quantified in available studies.

Low 🟥

Hepatotoxicity

Rare case reports have associated andrographis use with elevated liver enzymes and, less often, more significant hepatic injury, including isolated cases of acute hepatitis listed in the LiverTox database. The Prabhakornritta 2025 COVID-19 meta-analysis explicitly noted mild liver enzyme elevations as the predominant adverse signal in trials. Most cases resolve on discontinuation, and the underlying mechanism is unclear (idiosyncratic, dose-related, or possibly product contamination/adulteration).

Magnitude: Not quantified in available studies.

Andrographis is intensely bitter (“King of Bitters”), and even encapsulated forms can produce burping, dyspepsia (indigestion or upper-abdominal discomfort), and nausea, especially when taken on an empty stomach or in liquid form. These are typically tolerated but can lead to discontinuation in a subset of users.

Magnitude: Not quantified in available studies.

Headache and Fatigue

A subset of users report headache, lightheadedness, or unusual fatigue, particularly when first starting andrographis or at higher doses. These are typically mild and transient.

Magnitude: Not quantified in available studies.

Speculative 🟨

Reproductive and Fertility Effects

Animal studies in rodents have reported reduced fertility, antifertility effects, and disruption of spermatogenesis at high doses; these signals are inconsistent and have not been replicated in humans. Pregnancy is conventionally listed as a contraindication on the basis of these animal data and traditional use as an emmenagogue (an agent traditionally used to stimulate menstrual flow).

Bleeding Risk

Andrographolide inhibits platelet aggregation in vitro and in animal models, raising a theoretical concern about additive bleeding risk with anticoagulants and antiplatelet drugs. No large clinical bleeding signal has emerged in modern trials, but caution is widely recommended.

Hypotension

Animal models show modest blood-pressure-lowering effects through endothelial and antiplatelet mechanisms, and a few small clinical observations suggest mild blood pressure reductions; clinically meaningful hypotension (abnormally low blood pressure) has not been reported in healthy adults.

Long-Term Immunomodulation

Because andrographis broadly suppresses NF-κB and Th1/Th17 responses, very prolonged or high-dose use could in principle blunt host defense. Human data specifically addressing long-term immunomodulation are lacking, and traditional practice has favored short-course rather than continuous use.

Risk-Modifying Factors

  • Pregnancy and breastfeeding: Andrographis is conventionally contraindicated in pregnancy due to animal antifertility/abortifacient signals and traditional emmenagogue use; safety in lactation is unknown
  • Pre-existing liver disease: Individuals with chronic liver disease, elevated baseline ALT (alanine aminotransferase, a liver enzyme released into the blood when liver cells are injured) or AST (aspartate aminotransferase, another liver enzyme released with liver-cell injury), or concurrent hepatotoxic medications face higher theoretical risk from rare hepatotoxic events
  • Active bleeding risk or anticoagulation: Individuals on warfarin, direct oral anticoagulants (DOACs, drugs such as apixaban, rivaroxaban, dabigatran that prevent blood clots without requiring routine monitoring), or dual antiplatelet therapy face additive bleeding risk
  • Autoimmune disease and immunosuppression: Andrographis’s broad NF-κB and Th1/Th17 suppression could theoretically interact with biologic immunosuppressants used for autoimmune disease and may complicate management; conversely, this same mechanism is the basis of its therapeutic activity in ulcerative colitis and rheumatoid arthritis, so the risk-benefit balance is condition-specific
  • Allergic constitution: Individuals with a history of allergic reactions to other bitter herbs or unrelated severe allergies should start cautiously due to rare anaphylactic case reports
  • Genetic polymorphisms: CYP3A4 and CYP1A2 polymorphisms may influence the magnitude of pharmacokinetic interactions with co-administered drugs and indirectly the risk of supratherapeutic concentrations of those drugs
  • Sex-based differences: No consistent sex-based differences in adverse event rates have been identified in controlled trials, though animal reproductive toxicity data drive sex-specific guidance during pregnancy
  • Age-related considerations: Older adults with polypharmacy face the largest cumulative risk of CYP-mediated drug interactions; standard adult doses are otherwise generally well-tolerated across the age range
  • Baseline biomarker levels: Individuals with elevated baseline ALT/AST, low platelet count, or active autoimmune flares should be screened and monitored more closely than otherwise healthy adults

Key Interactions & Contraindications

  • Anticoagulants and antiplatelet drugs: Andrographis may potentiate the effect of warfarin, DOACs (apixaban, rivaroxaban, dabigatran, edoxaban), heparin, and antiplatelet agents (aspirin, clopidogrel, ticagrelor) through additive antiplatelet activity; severity: caution; clinical consequence: increased bleeding risk; mitigating action: avoid combination perioperatively (stop at least 7–10 days before elective surgery) and monitor INR (international normalized ratio, a standardized measure of warfarin’s effect on blood clotting) closely if combined with warfarin
  • Antihypertensive drugs: Andrographis may potentiate the blood-pressure-lowering effects of ACE inhibitors (angiotensin-converting enzyme inhibitors, drugs such as lisinopril, enalapril that lower blood pressure by blocking ACE), ARBs (angiotensin II receptor blockers, drugs such as losartan, valsartan that lower blood pressure by blocking angiotensin II at its receptor), calcium channel blockers (e.g., amlodipine, diltiazem), beta-blockers (e.g., metoprolol, carvedilol), and diuretics; severity: caution; clinical consequence: hypotension; mitigating action: monitor blood pressure at initiation
  • Immunosuppressants: Andrographis may interact unpredictably with calcineurin inhibitors (cyclosporine, tacrolimus), mycophenolate, azathioprine, corticosteroids, and biologic agents (e.g., adalimumab, infliximab, ustekinumab, vedolizumab); severity: caution to absolute contraindication in solid-organ transplant recipients; clinical consequence: altered immune control or interference with therapy; mitigating action: avoid combination unless under specialist guidance
  • CYP3A4 substrates: Andrographis can inhibit intestinal CYP3A4, potentially raising blood levels of CYP3A4 substrates including some statins (e.g., simvastatin, atorvastatin), midazolam, calcium channel blockers, and protease inhibitors; severity: caution; clinical consequence: altered drug exposure; mitigating action: separate dosing or monitor drug levels where clinically relevant
  • CYP1A2 substrates: Andrographis may modestly inhibit CYP1A2 and slow clearance of caffeine, theophylline, and some antidepressants; severity: monitor; clinical consequence: increased side effects of CYP1A2 substrates; mitigating action: lower-end dosing of stacked CYP1A2 substrates
  • Antidiabetic drugs: Additive glucose-lowering effects with metformin (a first-line oral antidiabetic that reduces hepatic glucose output and improves insulin sensitivity), sulfonylureas (e.g., glipizide, glyburide, drugs that increase insulin secretion), GLP-1 receptor agonists (e.g., semaglutide, liraglutide, drugs that mimic GLP-1 to lower blood glucose and slow gastric emptying), and insulin are plausible from animal data; severity: monitor; clinical consequence: hypoglycemia (low blood sugar) risk; mitigating action: glucose monitoring and dose adjustment
  • Hepatotoxic drug interactions: Concurrent use with high-dose acetaminophen (paracetamol, the active ingredient in Tylenol), methotrexate, isoniazid, or other hepatotoxic agents; severity: caution; clinical consequence: additive hepatotoxic risk given rare hepatotoxic case reports; mitigating action: avoid stacking, monitor liver enzymes
  • Over-the-counter medication interactions: OTC (over-the-counter) NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen) and OTC aspirin; severity: caution; clinical consequence: additive bleeding risk; mitigating action: avoid concurrent high-dose use. OTC antihistamines, decongestants (e.g., pseudoephedrine), and combination cold remedies; severity: none; clinical consequence: no documented clinically meaningful interactions. OTC acetaminophen at or above recommended doses; severity: caution; clinical consequence: additive hepatic load; mitigating action: stay within label dose
  • Supplement interactions: Stacking with other antiplatelet supplements (high-dose fish oil, vitamin E, Ginkgo biloba, garlic extract); severity: caution; clinical consequence: compounded bleeding risk; mitigating action: avoid simultaneous use without medical guidance. Combining with other CYP3A4 inhibitors (grapefruit juice, Hypericum perforatum/St. John’s wort); severity: monitor; clinical consequence: exaggerated drug interactions; mitigating action: review co-medication exposure
  • Additive effects with other anti-inflammatory supplements: Andrographis is commonly combined with curcumin (a polyphenol from turmeric with anti-inflammatory activity), boswellia (frankincense extract used for inflammation and joint pain), and Eleutherococcus senticosus (Siberian ginseng, an adaptogenic root traditionally combined with andrographis in Kan Jang); severity: none; clinical consequence: no reported adverse interactions. Additive blood-pressure lowering may occur with hawthorn, magnesium, taurine, and beetroot extract; severity: monitor; clinical consequence: hypotension; mitigating action: monitor blood pressure when stacking
  • Populations who should avoid andrographis:
    • Pregnant and breastfeeding women (animal antifertility/abortifacient signals; insufficient human safety data)
    • Solid organ transplant recipients on immunosuppressive therapy
    • Individuals with known hypersensitivity to andrographis or related Acanthaceae plants
    • Individuals with clinically significant chronic liver disease (e.g., Child-Pugh Class B or C, a clinical scoring system for severity of liver dysfunction) or unexplained ALT/AST elevations
    • Individuals on warfarin or dual antiplatelet therapy without specialist supervision
    • Children under 4 years (insufficient pediatric safety data for routine self-administration)
    • Those scheduled for elective surgery within 7–10 days

Risk Mitigation Strategies

  • Short-course use: Use andrographis in short courses (typically 5–14 days at the onset of respiratory symptoms, or defined treatment blocks for ulcerative colitis or osteoarthritis) rather than continuously for many months, consistent with both traditional practice and the trial-based evidence
  • Choose standardized, third-party-tested products: Select products standardized to a defined andrographolide content (e.g., 4–10% andrographolides for general extracts; specific marker content for branded extracts such as ParActin) and independently tested by ConsumerLab, NSF, or USP, especially given that one in five products on Amazon was reported to be of poor quality
  • Take with food: Take encapsulated andrographis with food to reduce gastrointestinal discomfort, dyspepsia, and bitter aftertaste, and to mitigate the empty-stomach exacerbation of nausea
  • Screen for pregnancy and contraception: Avoid andrographis in pregnancy and in those actively trying to conceive; women of reproductive age should be aware of animal antifertility data
  • Monitor liver function with extended use: For courses longer than 4 weeks or in individuals with hepatic risk factors, check ALT/AST at baseline and at 4–8 weeks; discontinue if liver enzymes rise >2–3× the upper limit of normal
  • Monitor blood pressure and glucose: For users on antihypertensive or antidiabetic medication, monitor blood pressure and fasting glucose at initiation and periodically to detect additive effects
  • Stop before surgery: Discontinue andrographis at least 7–10 days before elective surgery to mitigate bleeding-risk concerns, consistent with general herbal-perioperative guidance
  • Inform healthcare providers: Disclose andrographis use to all physicians, particularly when taking anticoagulants, antihypertensives, antidiabetics, or immunosuppressants, and before any procedure
  • Watch for allergic reactions: Discontinue immediately and seek medical evaluation for new rash, itching, breathing difficulty, throat tightness, or facial swelling
  • Avoid stacking with multiple antiplatelet supplements: Do not combine andrographis with high-dose fish oil, vitamin E, Ginkgo biloba, and garlic simultaneously without medical guidance, given additive antiplatelet potential

Therapeutic Protocol

Andrographis dosing varies substantially across preparations and indications, and the clinical trial literature reflects this heterogeneity. The protocols below reflect doses most commonly used in positive trials and approved monographs:

  • Standardized whole-extract for acute respiratory tract infection: 400 mg three times daily (1,200 mg/day total) of an extract standardized to approximately 4–6% andrographolide, started within 72 hours of symptom onset, for 5–7 days; alternatively, doses delivering 60–300 mg/day of andrographolide content
  • Kan Jang fixed combination (andrographis + Eleutherococcus senticosus): As labeled, typically 4 tablets twice or three times daily for 5–10 days; the combination has substantial European trial evidence for upper respiratory tract infection
  • HMPL-004 for active ulcerative colitis: 1,200–1,800 mg/day in divided doses for 8 weeks of induction, based on the Sandborn et al. 2013 phase II trial; this is an investigational pharmaceutical-grade preparation rather than a generic supplement
  • ParActin for osteoarthritis: 300 mg/day of standardized andrographis extract (ParActin) in divided doses for 12 weeks or longer based on Hancke et al. 2019 and follow-on trials
  • Andrographis for multiple sclerosis fatigue: 170 mg twice daily of a purified Andrographis paniculata extract for up to 12 months based on Bertoglio et al. 2016 pilot data
  • Best time of day: Andrographis can be taken at any time of day; ideal practice is with food and water to reduce gastrointestinal effects; for respiratory infections, dosing is typically every 6–8 hours
  • Single dose vs. split doses: Clinical trials almost uniformly use divided dosing (typically 2–3 times daily) to maintain relatively constant plasma andrographolide exposure given the short half-life
  • Half-life considerations: Andrographolide is rapidly absorbed (Tmax 1.5–2 hours) with an elimination half-life of approximately 2 hours, supporting divided dosing; bioavailability is non-linear, with disproportionately lower bioavailability at very high doses
  • Genetic polymorphisms: No pharmacogenomic guidelines exist for andrographis; theoretical considerations involving CYP3A4 and CYP1A2 variants have not been clinically validated for dosing
  • Sex-based differences: No sex-specific dosing adjustments are established in trials
  • Age-related considerations: Standard adult doses apply across ages 18–65; pediatric dosing has been used in trials at proportionally reduced doses (typically half the adult dose for older children); older adults with polypharmacy or hepatic/renal impairment may benefit from starting at the low end of the dose range
  • Baseline biomarker levels: No routine baseline testing is required for short respiratory courses; for extended use or in autoimmune indications, baseline ALT, AST, and CBC (complete blood count, a routine blood test measuring red cells, white cells, and platelets) are reasonable
  • Pre-existing health conditions: Pregnancy, transplant status, active immunosuppressive therapy, and uncontrolled liver disease should generally preclude andrographis use; ulcerative colitis and rheumatoid arthritis dosing should be supervised

Discontinuation & Cycling

  • Lifelong vs. short-term use: Andrographis is not intended as a lifelong daily supplement. Trial-based use patterns favor 5–14 days for acute respiratory infections, 8–12 weeks for ulcerative colitis induction, and 12 weeks to 12 months for osteoarthritis or multiple sclerosis fatigue under supervision; continuous year-round use is not supported by evidence
  • Withdrawal effects: No withdrawal effects, rebound phenomena, or dependence have been reported with andrographis discontinuation
  • Tapering: No tapering protocol is necessary; andrographis can be discontinued abruptly at any time
  • Cycling: A practical cycling pattern in European phytotherapy is short treatment courses separated by at least equal-length washout periods (e.g., 2 weeks on, 2 weeks off during high-exposure seasons), or simply reserving andrographis for acute illness and discrete inflammatory flares rather than continuous use
  • Long-course discontinuation: For users on extended courses (>3 months) for ulcerative colitis or osteoarthritis, discontinuation should follow a planned monitoring point (clinical assessment, lab testing) rather than abrupt cessation, primarily to detect potential disease relapse rather than for any pharmacologic withdrawal

Sourcing and Quality

  • Standardization: Look for products standardized to andrographolide content (typically 4–10% andrographolides, or labeled mg of andrographolide per dose); branded extracts with reproducible characterization include Kan Jang (with Eleutherococcus senticosus), ParActin (Pure Andrographis Standardized Extract), and HMPL-004 (investigational)
  • Third-party testing: ConsumerLab has reported that approximately one in five andrographis supplements sold on Amazon was of poor quality on recent independent testing, including products that did not contain the labeled amount of andrographolide. Choose products independently tested by ConsumerLab, NSF, or USP for identity, potency, purity, and contaminants
  • Reputable brands and formulations: Established options include Life Extension Andrographis (PARACTIN-based), Swedish Herbal Institute Kan Jang, Paradise Herbs Andrographis paniculata, Gaia Herbs Andrographis, and Nature’s Way Andrographis. Clinical trial preparations such as Kan Jang and ParActin have the most direct evidence support
  • Plant part and extraction: Most clinical evidence is from leaf and aerial-parts extracts using ethanol/water mixtures; root preparations are less common in modern trials. Standardized hydroethanolic extracts preserve diterpenoid lactones better than dried encapsulated whole-herb products
  • Avoid contamination risks: Choose brands that test for pesticide residues, heavy metals (especially lead, cadmium, and arsenic, which can accumulate in herbs), and microbial contamination; inadequately processed andrographis can be contaminated
  • Form considerations: Capsules and tablets dominate the consumer market; tinctures and fresh-pressed liquids are less common in modern trials. Avoid products that fail to specify plant part, extraction solvent, andrographolide content, or third-party testing

Practical Considerations

  • Time to effect: When used for acute respiratory infections, symptom relief (cough, sore throat) typically begins within 24–48 hours of starting standardized extract dosing. For ulcerative colitis induction, the trial-validated treatment window is 8 weeks. For osteoarthritis, meaningful pain reduction is generally observed by 4–12 weeks of continuous dosing
  • Common pitfalls:
    • Using non-standardized or misidentified products: commercial andrographis supplements vary substantially in andrographolide content, plant part, and extraction method; the clinical evidence does not apply uniformly to “andrographis” as a generic category
    • Starting too late: delaying andrographis until a respiratory infection is well established substantially reduces any treatment benefit
    • Under-dosing: many consumer products are labeled with total herb mass but undisclosed andrographolide content, often well below trial-evidence levels
    • Continuous long-term use: this is not supported by the evidence and runs counter to traditional practice
    • Using during pregnancy: a frequent safety error given easy availability of cold remedies
    • Combining with anticoagulants without monitoring: a clinically meaningful pitfall in older adults
    • Expecting a pharmaceutical-level effect outside ulcerative colitis: the effect sizes for cold and flu are real but moderate; the effect sizes for ulcerative colitis are larger but require pharmaceutical-grade extracts not available over-the-counter
  • Regulatory status: In the United States, andrographis products are classified as dietary supplements and are available without prescription. In the European Union, several standardized extracts (notably Kan Jang) are registered as Traditional Herbal Medicinal Products. Thailand has formally endorsed andrographis for early-symptom outpatient COVID-19 management since 2021. Sweden, Russia, and several Asian markets have national pharmacopeial monographs; the Indian Pharmacopoeia and the Chinese Pharmacopoeia both list standardized andrographis preparations
  • Cost and accessibility: Andrographis is inexpensive and widely available from pharmacies, health food stores, and online retailers. A typical short-course treatment costs approximately $5–15, and 1–3 months of standardized extract supply for ongoing use typically costs $20–60. Pharmaceutical-grade preparations (HMPL-004) are not commercially available

Interaction with Foundational Habits

  • Sleep: Andrographis has no direct sedating or stimulating effects and does not meaningfully interact with sleep; some users report mild headache or fatigue at high doses, which can affect perceived sleep quality. The mechanism is non-stimulant (NF-κB and TNF-alpha inhibition rather than monoamine modulation), so timing relative to bedtime is flexible
  • Nutrition: Andrographis is compatible with all dietary patterns. It does not deplete any specific nutrients. Taking it with food substantially reduces gastrointestinal discomfort and dyspepsia; very high-fat meals may modestly reduce andrographolide bioavailability through bile-acid effects, but the effect is small and clinically minor. Combining with curcumin, fish oil, or other anti-inflammatory dietary components is a common practice in integrative medicine
  • Exercise: Andrographis’s antiplatelet activity is mild but combined with vigorous endurance exercise and high-dose fish oil could marginally elevate bruising or bleeding risk in susceptible individuals. The herb does not appear to blunt training adaptation; observational data in monogastric animal models suggest modest increases in lean mass in some species, but this has not been demonstrated in human athletes. Users on anticoagulants should avoid combining andrographis with high-impact contact sports
  • Stress management: Andrographis is the bitter half of the classic Kan Jang adaptogenic combination with Eleutherococcus senticosus (Siberian ginseng); the combination has been used for adaptogenic and stress-resilience purposes, but the direct effects of andrographis monotherapy on cortisol or HPA axis (hypothalamic-pituitary-adrenal axis, the central neuroendocrine system regulating stress response) markers are not well documented. Mechanism-based effects on neuroinflammation suggest indirect cognitive and mood benefits during inflammatory episodes

Monitoring Protocol & Defining Success

Because andrographis is typically used for short courses or defined treatment blocks rather than as a continuous lifelong supplement, intensive biomarker monitoring is generally not required for most users. However, for individuals using andrographis for several weeks or for inflammatory indications such as ulcerative colitis or osteoarthritis, a focused monitoring framework can help define success and detect adverse effects.

Baseline assessments: For most healthy adults using a short course for respiratory infection, no baseline testing is required. For individuals using andrographis for longer than 4 weeks, the following may be considered:

  • ALT/AST and total bilirubin (a breakdown product of red blood cells, elevated in liver dysfunction or biliary obstruction) to detect baseline hepatic risk
  • CBC with platelets to establish baseline for bleeding-risk monitoring
  • Basic metabolic panel (BMP, a panel of blood tests including electrolytes, glucose, BUN, blood urea nitrogen, a marker of kidney function and protein metabolism, and creatinine, a waste product filtered by the kidneys used to estimate kidney function) for general safety
  • Disease-specific baseline (e.g., fecal calprotectin, a marker of intestinal inflammation, for ulcerative colitis; WOMAC for osteoarthritis)
  • 25-hydroxyvitamin D and serum zinc as more evidence-supported foundations of immune function for users targeting immune outcomes

Ongoing monitoring (cadence: at 4–8 weeks, then every 3–6 months for extended use; or at the end of any course longer than 14 days):

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT < 25 U/L (men), < 20 U/L (women) Detects rare hepatotoxicity Conventional reference: < 40 U/L; relevant for any course longer than 4 weeks or in users with hepatic risk factors
AST < 25 U/L Complementary marker of liver injury Conventional reference: < 40 U/L; paired with ALT for hepatic monitoring
Total bilirubin < 1.0 mg/dL Detects clinically significant hepatic dysfunction Conventional reference: < 1.2 mg/dL; relevant for extended use
Platelet count 150,000–400,000/microL Baseline for bleeding-risk monitoring Standard CBC range; relevant for users on anticoagulants or undergoing surgery
INR < 1.1 (off anticoagulation); target range per indication (on warfarin) Monitors warfarin effect when combined Relevant only if combined with warfarin; check at 1 week and after dose changes
hs-CRP < 1.0 mg/L Tracks systemic inflammation in inflammatory indications Conventional reference: < 3.0 mg/L; relevant for ulcerative colitis, rheumatoid arthritis, and osteoarthritis users
Fecal calprotectin < 50 micrograms/g Tracks intestinal inflammation in ulcerative colitis Conventional reference: < 50–120 micrograms/g; baseline and at 8 weeks for ulcerative colitis users
Fasting glucose 70–90 mg/dL Detects additive hypoglycemia with antidiabetic drugs Conventional reference: < 100 mg/dL; relevant for diabetic users
Blood pressure < 120/80 mmHg Detects additive hypotension with antihypertensives Conventional thresholds vary; home monitoring at 1, 2, and 4 weeks for users on antihypertensive drugs
25-hydroxyvitamin D 40–60 ng/mL Confirms adequacy of foundational immune-support nutrient Conventional reference: > 20 ng/mL; annual measurement

Qualitative markers to monitor:

  • Cold and flu frequency, duration, and severity across seasons (with and without andrographis)
  • Time from respiratory symptom onset to resolution during acute illness
  • Joint pain, stiffness, and function scores (e.g., WOMAC) in osteoarthritis and rheumatoid arthritis users
  • Bowel symptom diary (stool frequency, blood, urgency, abdominal pain) in ulcerative colitis users
  • Fatigue scales (e.g., Fatigue Severity Scale) in multiple sclerosis users
  • New rash, itching, or signs of allergic reaction
  • Unexplained bruising, bleeding gums, or epistaxis (nosebleed) suggesting bleeding-risk effects
  • New jaundice (yellowing of skin and eyes from elevated bilirubin) or right-upper-quadrant abdominal pain suggesting hepatic injury
  • Overall subjective well-being during defined treatment blocks

Emerging Research

Several ongoing clinical trials and research directions may refine the evidence base for andrographis:

  • COVID-19 and other emerging respiratory viruses: The 2025 Prabhakornritta meta-analysis (2025) consolidated evidence that andrographis does not significantly improve fever or cough resolution versus standard care in mild-to-moderate COVID-19; further trials of specific extracts and herbal-combination regimens (e.g., the completed NCT06636760, a randomized trial of a herbal combination including Andrographis paniculata with 66 adult outpatients and primary endpoints of clinical symptom improvement, WHO ordinal scale change, EQ-5D-5L quality of life, and time to respiratory rate normalization) and any future replication studies will determine whether subgroup or formulation effects exist
  • Cardio-metabolic and obesity research: Indonesian quasi-experimental studies (NCT06520527, 30 obese adults, primary endpoint change in systolic and diastolic blood pressure, and NCT06520501, 30 obese adults, primary endpoint change in blood glucose) compare andrographis with brisk walking exercise in obese adults; results may clarify the magnitude and clinical relevance of metabolic effects, and additional adequately powered RCTs are needed in this domain
  • Knee osteoarthritis: The completed long-exposure ParActin trial in knee osteoarthritis (NCT04833946, 80 participants, industry-sponsored by Vedic Lifesciences, primary endpoint joint space narrowing on MRI at 336 days) provides chronic-use data on cartilage and pain outcomes, extending the Hancke et al. 2019 RCT into a longer timeframe; independent replication outside the manufacturer-funded program remains a key open need
  • Migraine prophylaxis: A completed observational study (NCT04463875, 2018–2020, observational, 113 episodic migraine patients, primary endpoint headache frequency reduction) evaluating a fixed combination of magnesium, vitamin B2, feverfew, Andrographis paniculata, and coenzyme Q10 suggests andrographis warrants further controlled testing as part of a multi-target preventive regimen
  • Cognitive impairment in older adults: A small phase I trial (NCT03780621, phase I, 16 participants, primary endpoint EEG marker change) evaluates an andrographis-and-Withania somnifera combination in mild cognitive impairment, an early step toward neurocognitive applications
  • Multiple sclerosis fatigue: Building on the Bertoglio et al. 2016 pilot and the Hancke MS trial, further trials are needed to confirm the fatigue signal in larger relapsing-remitting multiple sclerosis cohorts
  • Esophageal cancer palliation: A completed phase III trial in advanced esophageal squamous cell carcinoma (NCT04196075) tests andrographis as palliative therapy, exploring the anti-proliferative signal seen in preclinical models
  • Bioavailability and formulation science: Ongoing pharmacokinetic and formulation work, including the Songvut et al. 2025 high-dose pharmacokinetic study, aims to address andrographolide’s non-linear oral bioavailability through self-emulsifying drug delivery systems, nanoparticle formulations, and bioenhancer combinations, which may reshape future trials and dosing recommendations
  • HMPL-004 in ulcerative colitis: Pharmaceutical development of HMPL-004 for ulcerative colitis was deprioritized after phase II, but the published data continue to motivate exploration of andrographolide derivatives as inflammatory bowel disease therapies

Conclusion

Andrographis is a centuries-old bitter herb that has crossed over into modern phytotherapy with stronger evidence than most traditional remedies. Multiple meta-analyses converge on a real and clinically meaningful benefit for symptomatic relief of acute respiratory tract infections, particularly when started within the first three days of symptom onset using standardized extracts. A pharmaceutical-grade preparation has shown meaningful response rates in active inflammatory bowel disease comparable to standard treatment, and brand-standardized extracts have produced reproducible pain and function improvements in knee joint inflammation. Smaller bodies of evidence point to plausible benefits in multiple sclerosis-related fatigue, rheumatoid arthritis, and insulin sensitivity. By contrast, the pandemic-era respiratory virus evidence has not held up under meta-analysis, and broader anticancer and liver-protective claims remain preclinical. A meaningful share of the supportive trials are sponsored or funded by extract manufacturers, which is a structural factor when weighing the strength of the evidence.

Most adverse events are mild gastrointestinal or skin-related; serious events are very rare in pooled trial data, but a small signal of liver enzyme elevation, allergic reactions, and antiplatelet activity warrants attention. Pregnancy and active immunosuppression are firm contraindications, and product quality varies significantly across the consumer market.

From a health and longevity perspective, andrographis is best viewed as a short-course or defined-block adjunct for specific inflammatory and respiratory situations rather than as a continuous lifelong supplement, with effect sizes that are real, generally modest outside inflammatory bowel disease, and dependent on choosing a properly standardized, third-party-tested product.

Top - Benefits - Risks - Protocol